Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Imetit. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A known ✓ | P08913 | 2/20 | 0.50 |
| ▸ | HRH4 | Q9H3N8 | 5/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | THPO | P40225 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | NOS1 | P29475 | 6/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | IDO1 | P14902 | 2/20 | 0.42 |
| ▸ | NOS3 | P29474 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Imetit SCHEMBL31157603 | 1.00 | HRH4 (0.50) | HRH4NPSR1HRH3ADRA2ABLM | |
| Imetit SCHEMBL2895693 | 0.98 | HRH4 (0.49) | HRH4NPSR1HRH3ADRA2ABLM | |
| SCHEMBL27550976 | 0.89 | HRH4 (0.51) | HRH4NPSR1HRH3ADRA2ABLM | |
| SCHEMBL31157604 | 0.78 | — | — | |
| Histamine SCHEMBL27489895 | 0.76 | HRH4 (0.34) | HRH4HRH3TDP1TSHRCYP2C19 | |
| Histamine SCHEMBL29399326 | 0.74 | — | — | |
| Histamine SCHEMBL4202201 | 0.74 | HRH4 (0.41) | HRH4HRH3TDP1LMNAAPEX1 | |
| SCHEMBL2893700 | 0.72 | SPHK2 (0.31) | LMNA | |
| Histamine SCHEMBL28543874 | 0.72 | HRH4 (0.39) | HRH4HRH3TDP1LMNAAPEX1 | |
| Histamine SCHEMBL4234179 | 0.72 | HRH4 (0.39) | HRH4HRH3TDP1LMNAAPEX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230035892-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | FLAGSHIP PIONEERING, INC. | 2023-02-02 | — | — | US | disclosed |
| US-20220033490-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER USING CHRNA6 INHIBITORS | FLAGSHIP PIONEERING INNOVATIONS V INC (US) | 2022-02-03 | — | — | US | disclosed |
| US-20210283217-A1 | NEUROMODULATING COMPOSITIONS AND RELATED THERAPEUTIC METHODS FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | FLAGSHIP PIONEERING INNOVATIONS V, INC. | 2021-09-16 | — | — | US | disclosed |
| US-11059886-B1 | Methods and compositions for treating inflammatory or autoimmune diseases or conditions using GRM8 activators | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2021-07-13 | — | — | US | disclosed |
| US-20210177823-A1 | NEUROMODULATING COMPOSITIONS AND RELATED THERAPEUTIC METHODS FOR THE TREATMENT OF CANCER | FLAGSHIP PIONEERING INNOVATIONS V, INC. | 2021-06-17 | — | — | US | disclosed |
| US-11034751-B1 | Methods and compositions for treating cancer using serotonin receptor inhibitors | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-20210154272-A1 | NEUROMODULATING COMPOSITIONS AND RELATED THERAPEUTIC METHODS FOR THE TREATMENT OF CANCER BY MODULATING AN ANTI-CANCER IMMUNE RESPONSE | FLAGSHIP PIONEERING INNOVATIONS V, INC. | 2021-05-27 | — | — | US | disclosed |
| US-11013717-B1 | Methods and compositions for treating cancer using SERCA pump inhibitors | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2021-05-25 | — | — | US | disclosed |
| US-20200360364-A1 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY OR AUTOIMMUNE DISEASES OR CONDITIONS USING CHRNA6 ACTIVATORS | FLAGSHIP PIONEERING INNOVATIONS V INC (US) | 2020-11-19 | — | — | US | disclosed |
| US-10683352-B1 | Methods for treating cancer using GRM8 inhibitors | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2020-06-16 | — | — | US | disclosed |
| US-20190240293-A1 | NEUROMODULATING COMPOSITIONS AND RELATED THERAPEUTIC METHODS FOR THE TREATMENT OF CANCER BY MODULATING AN ANTI-CANCER IMMUNE RESPONSE | CYGNAL THERAPEUTICS, INC. | 2019-08-08 | — | — | US | disclosed |
| US-20190233527-A1 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY OR AUTOIMMUNE DISEASES OR CONDITIONS USING CALCITONIN RECEPTOR ACTIVATORS | FLAGSHIP PIONEERING, INC. | 2019-08-01 | — | — | US | disclosed |
| EP-3506926-A1 | NEUROMODULATING COMPOSITIONS AND RELATED THERAPEUTIC METHODS FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | Flagship Pioneering Innovations V, Inc. (US) | 2019-07-10 | — | — | EP | disclosed |
| EP-3490581-A2 | NEUROMODULATING COMPOSITIONS AND RELATED THERAPEUTIC METHODS FOR THE TREATMENT OF CANCER | Flagship Pioneering Innovations V, Inc. (US) | 2019-06-05 | — | — | EP | disclosed |
| EP-3490542-A1 | NEUROMODULATING COMPOSITIONS AND RELATED THERAPEUTIC METHODS FOR THE TREATMENT OF CANCER BY MODULATING AN ANTI-CANCER IMMUNE RESPONSE | Flagship Pioneering Innovations V, Inc. (US) | 2019-06-05 | — | — | EP | disclosed |
| WO-2018022668-A2 | NEUROMODULATING COMPOSITIONS AND RELATED THERAPEUTIC METHODS FOR THE TREATMENT OF CANCER | FLAGSHIP PIONEERING, INC. (US) | 2018-02-01 | — | — | WO | disclosed |
| WO-2018022666-A1 | NEUROMODULATING COMPOSITIONS AND RELATED THERAPEUTIC METHODS FOR THE TREATMENT OF CANCER BY MODULATING AN ANTI-CANCER IMMUNE RESPONSE | FLAGSHIP PIONEERING, INC. (US) | 2018-02-01 | — | — | WO | disclosed |
| WO-2018022664-A1 | NEUROMODULATING COMPOSITIONS AND RELATED THERAPEUTIC METHODS FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | FLAGSHIP PIONEERING, INC. (US) | 2018-02-01 | — | — | WO | disclosed |
| US-RE37303-E1 | Imidazole compounds and their therapeutic applications | INSTITUT NATIONAL DEL LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2001-07-31 | — | — | US | disclosed |
| US-5559113-A | ANTAGONISTS TO HISTAMINE H3 RECEPTORS, SEDATIVES, ANTICONVULSANTS, ANTIULCER AGENTS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE | 1996-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220033490-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER USING CHRNA6 INHIBITORS | CHRNA6, CHRNA1, CHRNB1 | ADRA2A 45/4885HRH4 869/4885NPSR1 822/4885 |
| US-20200360364-A1 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY OR AUTOIMMUNE DISEASES OR CONDITIONS USING CHRNA6 ACTIVATORS | CHRNA6, CHRNA1, CHRNG | ADRA2A 58/4885HRH4 428/4885NPSR1 735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.